Mayor Zohran Mamdani's first city budget locks in permanent funding for a program that pays drug users up to $10 a day to return used needles, and one participant already calls it her "side hustle."
The Community Syringe Redemption Program, which launched as a pilot in March 2025, now has a $3 million line item inside New York City's $126 billion spending plan. Budget documents submitted to the City Council on June 30 included the allocation, and lawmakers approved it shortly after. The money comes from more than $189 million in opioid settlement funds the city secured from manufacturers and distributors.
The program pays enrolled participants 20 cents for each used syringe dropped off at one of eight designated redemption sites, five in the Bronx, and one each in Brooklyn, Manhattan, and Queens. Daily payouts cap at 50 syringes, or $10. In its first year, the city paid out roughly $292,000 to more than 1,700 participants and collected more than 2.3 million used needles, Fox News reported.
The sharpest criticism centers on where the dollars originate. Opioid settlement funds were wrung from the pharmaceutical companies and distributors whose products fueled an addiction crisis that has hollowed out families and neighborhoods across the country. Critics say those dollars were meant to help people get clean, not to hand cash to active users.
Queens Republican Councilwoman Joann Ariola put it bluntly. The settlement money, she said:
"should all be going toward addiction treatment services, not for paying users to turn in their needles for cash."
Ariola went further, telling the New York Post that the program "is putting money in the pockets of addicts" rather than helping them break free of their addiction.
She is not alone. Bronx Democratic Councilman Oswald Feliz, a member of the mayor's own party, credited the effort to clear discarded syringes but warned that the city "should not recklessly create conditions that can threaten the safety of vulnerable communities." When a Bronx Democrat raises that flag, the concern is bipartisan.
The city's own participant testimony does little to reassure skeptics. Tamia Wright, a 43-year-old who returns used needles at a park in the Bronx, told the Post the program had become "definitely a side hustle." Asked what she planned to spend the money on, Wright was candid: "weed... and cigarettes."
That is not a recovery story. It is a taxpayer-funded errand that, by one participant's own admission, subsidizes more substance use. And it is now permanently embedded in the city budget.
Health Department spokesperson Rachel Vick defended the initiative, saying it helps residents "live in a community free of syringe litter" while safely disposing of medical waste and connecting people in need with nearby care. The city also points to Sanitation Department data showing that discarded-needle collection dropped from 64,560 to 26,229 when comparing the same period year over year, a decline officials attribute in part to the buyback program.
Running the day-to-day operation is Addiction Response Resources, a nonprofit that holds an $11.1 million contract with the city extending through the end of next year. The same organization operates a similar syringe redemption program in Boston, Newsmax reported.
The numbers deserve a closer look. The program collected 2.3 million syringes over roughly 16 months and paid out $292,000 in its first year. At 20 cents per needle, that math checks out, but the overhead does not explain itself. An $11.1 million contract and a $3 million annual budget allocation dwarf the $292,000 in direct participant payments. Where the rest of the money goes is a question taxpayers and council members are entitled to ask.
New York City Council members passed the enabling legislation in 2022, backed primarily by progressive members. At the time, it was framed as a pilot, a temporary experiment. Making it permanent through Mamdani's first budget signals that the current administration views harm-reduction cash payouts not as a stopgap but as standing policy.
The program's defenders lean on the needle-litter reduction data, and those numbers are real. Fewer discarded syringes on playgrounds and sidewalks is a genuine public-safety gain. No one wants a child stepping on a used needle in a Bronx park.
But the program does not address the underlying crisis. It does not fund a single detox bed. It does not pay for a single counselor. It does not require participants to engage with treatment as a condition of enrollment. It pays people who use drugs a small daily sum and sends them on their way, sometimes, by their own account, to buy more drugs.
Opioid settlement funds exist because communities demanded accountability from the companies that flooded American neighborhoods with addictive painkillers. Those dollars represent a finite, hard-won resource. Every dollar spent paying someone 20 cents a needle is a dollar not spent on residential treatment, medication-assisted recovery, or the counselors that overwhelmed community health centers desperately need.
The broader debate over harm-reduction policy is not new, but the scale of New York's commitment is notable. Three million dollars a year, eight fixed sites, an $11.1 million nonprofit contract, this is infrastructure, not an experiment. And once infrastructure exists, it rarely shrinks.
Mayor Mamdani's $126 billion budget had room for plenty of line items. He chose to make permanent a program that hands cash to active drug users, funded by settlement money extracted from the very industry that created the addiction epidemic. The city's own participant told a reporter she treats the program as a side gig to buy marijuana and cigarettes.
Five of the eight redemption sites sit in the Bronx, the borough already bearing the heaviest burden of the opioid crisis. Councilman Feliz's warning about "recklessly" creating dangerous conditions for vulnerable communities was aimed squarely at his own constituents. Those residents did not ask for a needle-buyback kiosk. They asked for safer streets and fewer addicts.
The Sanitation Department's year-over-year needle data shows improvement, and that improvement matters. But measuring success by how many syringes you buy back is like measuring fire safety by how many extinguishers you hand out while ignoring the arsonist. The needles are a symptom. The addiction is the disease. And New York City just permanently funded a program that treats the symptom while leaving the disease untouched.
When the opioid settlement money runs out, and finite pots of money always do, New York will have spent millions paying people to do what a sharps-disposal bin does for free. The addicts will still be addicted. And the city will call it progress.
